BASEL, Switzerland,
July 10, 2017 /PRNewswire/
-- Dermavant Sciences, a biopharmaceutical company dedicated
to developing and commercializing innovative therapies in medical
dermatology, today announced the appointment of Dr. Jacqualyn
"Jackie" Fouse as Executive Chairman.
"I am honored to lead Dermavant and look forward to building the
world's leading innovative medical dermatology company," said Dr.
Fouse. "For the past decade there has been an 'innovation gap' in
medical dermatology, with surprisingly few novel therapies despite
a greater understanding of the pathophysiology of many dermatologic
conditions. Physicians and patients are eager for better
options."
"In less than two years, Dermavant has created a robust pipeline
of promising potential therapies targeting multiple indications,"
Dr. Fouse continued. "I believe the company is well on its way to
being the ideal development and commercialization partner for
innovative dermatology medicines. I am impressed with the quality
of the Dermavant team and the entire Roivant organization."
"We are delighted to welcome Jackie to the helm of Dermavant,"
said Vivek Ramaswamy, Founder and
Chief Executive Officer of Roivant Sciences. "She is an exceptional
leader and one of the most admired executives in the
biopharmaceutical industry. Jackie is emblematic of the caliber of
leadership that we seek to attract to the Roivant family of
companies."
Dr. Fouse previously served as President and Chief Operating
Officer of Celgene Corporation until April
2017, and as a member of Celgene's Board of Directors
through June 2017. She joined Celgene
in 2010 as Chief Financial Officer and was named president of the
company's global Hematology & Oncology franchise in 2014. Her
experience at Celgene included working closely with the business
unit that launched OTEZLA® for the treatment of moderate-to-severe
plaque psoriasis and active psoriatic arthritis.
Before joining Celgene, Dr. Fouse served as Chief Financial
Officer of Bunge Limited, a leading global agribusiness and food
company. Prior to Bunge, she served as Senior Vice President, Chief
Financial Officer, and Head of Corporate Strategy at Alcon
Laboratories, a leading ophthalmic pharmaceutical and medical
device company. Prior to her tenure with Alcon, she held a variety
of senior leadership roles with international companies, spending
almost a decade of her career in Switzerland. Dr. Fouse earned her B.A. and
M.A. in Economics and a Ph.D. in Finance from the University of Texas at Arlington.
About Dermavant Sciences
Dermavant Sciences is dedicated to developing and, upon
regulatory approval, commercializing innovative therapies in
medical dermatology. Dermavant currently has three investigational
drugs in development: RVT-501, RVT-502, and RVT-201. RVT-501 is a
highly potent and selective topical phosphodiesterase-4 inhibitor
currently in a Phase 2 clinical program for patients with
mild-to-moderate atopic dermatitis. RVT-502, also known as
cerdulatinib, is a dual spleen tyrosine kinase (Syk) and janus
kinase (JAK) inhibitor being developed as a topical therapy for a
variety of serious dermatologic conditions. RVT-201 is a caspase-1
inhibitor that acts to inhibit the production of inflammatory
cytokines and is being developed for inflammatory skin diseases.
For more information, please visit dermavantsciences.com.
About Roivant Sciences
Roivant Sciences is dedicated to realizing the full potential of
promising biomedical research by developing and commercializing
novel therapies across diverse therapeutic areas. Roivant partners
with innovative biopharmaceutical companies and academic
institutions to ensure that important medicines are rapidly
developed and delivered to patients. Roivant advances its drug
pipelines through wholly- or majority-owned subsidiary companies,
including Axovant (NYSE: AXON) (neurology), Myovant (NYSE: MYOV)
(women's health and endocrine diseases), Dermavant (dermatology),
Enzyvant (rare diseases), and Urovant (urology). Roivant's partners
include Merck, Takeda Pharmaceuticals, GlaxoSmithKline, Eisai,
Vertex Pharmaceuticals, Duke
University, and Cincinnati Children's Hospital Medical
Center. Roivant's long-range mission is to reduce the time and cost
of developing new medicines for patients. For more information,
please visit roivant.com.
OTEZLA® is a registered trademark of Celgene Corporation.
Related Links
www.dermavantsciences.com
View original
content:http://www.prnewswire.com/news-releases/dermavant-sciences-appoints-dr-jacqualyn-fouse-as-executive-chairman-300485011.html
SOURCE Dermavant Sciences